Species |
Human |
Protein Construction |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer [Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and HMTEVVRHC peptide] Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&HMTEVVRHC |
His |
Avi |
N-term |
|
C-term |
|
Conjugate |
Biotin |
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind Anti-HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Antibody, hFc Tag. Test result was comparable to standard batch. |
Expression System |
E.coli |
Theoretical Molecular Weight |
35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) |
Apparent Molecular Weight |
The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
![HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06477 ELISA.jpg&file=scm_files/productFile_notes/2025/04/25/Z06477 ELISA.jpg)
Immobilized HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Anti-HLA-A*02:01&B2M&P53 R175H Antibody, hFc Tag with the EC50 of 3.2 ng/ml determined by ELISA.
![HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06477 HPLC.png&file=scm_files/productFile_notes/2025/04/25/Z06477 HPLC.png)
The purity of HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.
![HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06477 PAGE.png&file=scm_files/productFile_notes/2025/04/25/Z06477 PAGE.png)
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Target Background |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. |
Synonyms |
MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.